GeoVax Labs (GOVX) 10-Q 13 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 13, 2019
Document Information [Line Items]
Entity Registrant Name	GeoVax Labs, Inc.
Entity Central Index Key	0000832489
Trading Symbol	govx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		610,089
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
ASSETS
Cash and cash equivalents	$ 175,985	$ 259,701
Grant funds and other receivables	160,277	121,814
Prepaid expenses and other current assets	111,647	238,189
Total current assets	447,909	619,704
Property and equipment, net (Note 5)	13,725	11,350
Deposits	11,010	11,010
Total assets	472,644	642,064
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIENCY)
Accounts payable	253,166	125,859
Accrued expenses (Note 6)	1,378,710	1,238,552
Current portion of notes payable (Note 7)	12,500	260,420
Total current liabilities	1,644,376	1,624,831
Note payable, net of current portion (Note 7)	35,417	39,580
Total liabilities	1,679,793	1,664,411
Commitments (Note 8)
Stockholders’ equity (deficiency):
Common stock, $.001 par value: authorized shares – 600,000,000 issued and outstanding shares – 556,489 and 437,807 at March 31, 2019 and December 31, 2018, respectively	556	438
Additional paid-in capital	37,898,525	37,482,766
Accumulated deficit	(41,178,338)	(40,476,884)
Total stockholders’ equity (deficiency)	(1,207,149)	(1,022,347)
Total liabilities and stockholders’ equity (deficiency)	472,644	642,064
Series B Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	76,095	76,095
Series C Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock		705,238
Series E Convertible Preferred Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock		1,190,000
Conversion of Series F Preferred Stock Into Common Stock [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	1,591,763
Series G Convertible Preferred Stock and Related Warrants [Member]
Stockholders’ equity (deficiency):
Convertible Preferred Stock	$ 404,250

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	556,489	437,807
Common stock, shares outstanding (in shares)	556,489	437,807
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	100	100
Preferred stock, shares outstanding (in shares)	100	100
Series C Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	0	2,150
Preferred stock, shares outstanding (in shares)	0	2,150
Series E Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	0	1,200
Preferred stock, shares outstanding (in shares)	0	1,200
Conversion of Series F Preferred Stock Into Common Stock [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	2,583	0
Preferred stock, shares outstanding (in shares)	2,583	0
Series G Convertible Preferred Stock and Related Warrants [Member]
Preferred stock, par value (in dollars per share)	$ 1,000	$ 1,000
Preferred stock, shares issued (in shares)	500	0
Preferred stock, shares outstanding (in shares)	500	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Grant and collaboration revenues	$ 364,232	$ 221,299
Operating expenses:
Research and development	555,718	486,994
General and administrative	510,064	357,228
Total operating expenses	1,065,782	844,222
Loss from operations	(701,550)	(622,923)
Other income (expense):
Interest income	1,224	1,318
Interest expense	(1,128)	(208)
Total other income (expense)	96	1,110
Net loss	$ (701,454)	$ (621,813)
Basic and diluted:
Net loss per common share (in dollars per share)	$ (1.43)	$ (2.50)
Weighted average shares outstanding (in shares)	491,707	248,340

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes In Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Common Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Series E Convertible Preferred Stock [Member]	Series F Convertible Preferred Stock [Member]	Series G Convertible Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2017	213,474	100	2,570	1,000
Balance at Dec. 31, 2017	$ 213	$ 76,095	$ 842,990	$ 980,000				$ 35,696,435	$ (37,916,790)	$ (321,057)
Sale of convertible preferred stock for cash (in shares)					600
Sale of convertible preferred stock for cash					$ 590,000					590,000
Issuance of common stock for services (in shares)	10,000
Issuance of common stock for services	$ 10							199,990		200,000
Conversion of preferred stock to common stock (in shares)	60,000			(450)
Conversion of preferred stock to common stock	$ 60			$ (441,000)				440,940
Stock-based compensation expense								23,978		23,978
Net loss									(621,813)	(621,813)
Balance (in shares) at Mar. 31, 2018	283,474	100	2,570	550	600
Balance at Mar. 31, 2018	$ 283	$ 76,095	$ 842,990	$ 539,000	$ 590,000			36,361,343	(36,538,603)	(128,892)
Balance (in shares) at Dec. 31, 2018	437,807	100	2,150		1,200
Balance at Dec. 31, 2018	$ 438	$ 76,095	$ 705,238		$ 1,190,000			37,482,766	(40,476,884)	(1,022,347)
Sale of convertible preferred stock for cash (in shares)							500
Sale of convertible preferred stock for cash							$ 404,250	85,750		490,000
Conversion of preferred stock to common stock (in shares)	118,280		(587)			(180)
Conversion of preferred stock to common stock	$ 118		$ (192,557)			$ (110,918)		303,357
Stock-based compensation expense								26,652		26,652
Net loss									(701,454)	(701,454)
Exchange of preferred stock (in shares)			(1,563)		(1,200)	2,763
Exchange of preferred stock			$ (512,681)		$ (1,190,000)	$ 1,702,681
Fractional shares issuable upon reverse stock split (in shares)	402
Balance (in shares) at Mar. 31, 2019	556,489	100				2,583	500
Balance at Mar. 31, 2019	$ 556	$ 76,095				$ 1,591,763	$ 404,250	$ 37,898,525	$ (41,178,338)	$ (1,207,149)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (701,454)	$ (621,813)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,897	4,980
Stock-based compensation expense	153,224	52,549
Changes in assets and liabilities:
Grant funds and other receivables	(38,463)	54,758
Prepaid expenses and other current assets	(30)	20,848
Accounts payable and accrued expenses	267,465	107,105
Total adjustments	384,093	240,240
Net cash used in operating activities	(317,361)	(381,573)
Cash flows from investing activities:
Purchase of property and equipment	(4,272)
Net cash used in investing activities	(4,272)
Cash flows from financing activities:
Net proceeds from sale of preferred stock	240,000	590,000
Proceeds from issuance of note payable		50,000
Principal repayment of note payable	(2,083)
Net cash provided by financing activities	237,917	640,000
Net increase (decrease) in cash and cash equivalents	(83,716)	258,427
Cash and cash equivalents at beginning of period	259,701	312,727
Cash and cash equivalents at end of period	$ 175,985	$ 571,154

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parentheticals) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Series G Convertible Preferred Stock Issued in Exchange for Cancellation of Term notes Payable [Member]
Convertible note, shares issued (in shares)	250
Convertible note, value	$ 250,000
Conversion of Series C Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)	1,563
Conversion of Series E Preferred Stock Into Series F Preferred Stock [Member]
Convertible preferred stock (in shares)	1,200
Conversion of Series C and Series E Preferred Stock Into Series F Preferred Stock [Member]
Conversion of stock, shares issued (in shares)	2,763
Conversion of Series C Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)	587
Conversion of stock, shares issued (in shares)	78,280
Conversion of Series F Preferred Stock Into Common Stock [Member]
Convertible preferred stock (in shares)	180
Conversion of stock, shares issued (in shares)	40,000
Conversion From Series D Convertible Preferred Stock To Common Stock [Member]
Convertible preferred stock (in shares)		450
Conversion of stock, shares issued (in shares)		60,000

Note 1 - Description of Busines

Note 1 - Description of Business	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Nature of Operations [Text Block]	1. GeoVax Labs, Inc. (“GeoVax” or the “Company”), is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancers using a novel patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) vaccine platform. In this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into highly effective VLP immunogens in the person being vaccinated. The MVA-VLP virus replicates to high titers in approved avian cells for manufacturing but cannot productively replicate in mammalian cells. Therefore, the GeoVax MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live attenuated virus, while providing the safety characteristics of a replication-defective vector. Our current development programs are focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. We believe our technology and vaccine development expertise are well-suited for a variety of human infectious diseases and we intend to pursue further expansion of our product pipeline. Our corporate strategy is to improve health to patients worldwide by advancing our vaccine platform, using its unique capabilities to design and develop an array of products addressing unmet medical needs in the areas of infectious diseases and oncology. We aim to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials. We operate in a highly regulated and competitive environment. The manufacturing and marketing of pharmaceutical products require approval from, and are subject to, ongoing oversight by the Food and Drug Administration (FDA) in the United States, by the European Medicines Agency (EMA) in the European Union, and by comparable agencies in other countries. Obtaining approval for a new pharmaceutical product is never certain, may one GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Basis of Accounting [Text Block]	2. The accompanying condensed consolidated financial statements at March 31, 2019 three March 31, 2019 2018 not 10 December 31, 2018. not As described in Note 12, April 30, 2019, one five hundred Our financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve We believe that our existing cash resources, government funding commitments, and equity funding commitments discussed in Note 9 third 2019. not may not

Note 3 - Summary of Significant

Note 3 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. We disclosed in Note 2 10 December 31, 2018 no 10 In February 2016, No. 2016 02, Leases 2016 02 2016 02 not 12 12 2016 02 January 1, 2019; no 12 8 There have been no three March 31, 2019, 10 December 31, 2018,

Note 4 - Basic and Diluted Loss

Note 4 - Basic and Diluted Loss Per Common Share	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	4. Basic net loss per share is computed using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares and potentially dilutive common share equivalents outstanding during the period. Potentially dilutive common share equivalents consist of convertible preferred stock, stock options and stock purchase warrants. Common share equivalents which potentially could dilute basic earnings per share in the future, and which were excluded from the computation of diluted loss per share, as the effect would be anti-dilutive, totaled approximately 589,000 446,000 March 31, 2019 2018,

Note 5 - Property and Equipment

Note 5 - Property and Equipment	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2019 December 31, 2018: March 31, 2019 December 31, 2018 Laboratory equipment $ 534,578 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 678,868 674,596 Accumulated depreciation and amortization (665,143 ) (663,246 ) Property and equipment, net $ 13,725 $ 11,350

Note 6 - Accrued Expenses

Note 6 - Accrued Expenses	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	6. Accrued expenses as shown on the accompanying Condensed Consolidated Balance Sheets is composed of the following as of March 31, 2019 December 31, 2018: March 31, 2019 December 31, 2018 Accrued management salaries $ 1,026,467 $ 924,509 Accrued directors’ fees 333,870 295,670 Other accrued expenses 18,373 18,373 Total accrued expenses $ 1,378,710 $ 1,238,552

Note 7 - Notes Payable

Note 7 - Notes Payable	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Debt Disclosure [Text Block]	7. On February 28, 2018, five $50,000. 5%, second $8,333 2019, $12,500 2020, 2021 2022, $2,083 2023. five 358 three March 31, 2019 2018 $621 $208, On December 27, 2018, two $250,000. three 20,000 February 2019, 9

Note 8 - Commitments

Note 8 - Commitments	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Commitments Disclosure [Text Block]	8. Lease Agreement We lease approximately 8,400 December 31, 2019, December 31, 2022. three March 31, 2019 2018 $40,316 $39,136, $120,949 2019. one 90 Other Commitments In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of March 31, 2019, $487,000 2019.

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	9. Series B Preferred Stock As of March 31, 2019, 100 may $175 three March 31, 2019, no Series F Preferred Stock On February 18, 2019, 2,763 $1,000 no not $7.50 90% may, During January February 2019 ( 587 78,280 March 2019 ( 180 40,000 March 31, 2019, no 2,583 Series G Preferred Stock On February 25, 2019, 1,000 $1.0 three $1,000 no not $7.50 90% may, At the first February 26, 2019, 500 $250,000 7 $250,000. first 33,334 $7.50 six five first may, Within 50 60 first may $250,000 second 110 to120 first may $250,000 third second third may 66,668 During the three March 31, 2019, no Common Stock Transactions As discussed above, during the three March 31, 2019, 118,280 Stock Options During the three March 31, 2019, no March 31, 2019, 29,441 $53.19/share 13,585 $93.92/share Stock Purchase Warrants During the three March 31, 2019, 33,334 March 31, 2019, 148,032 $11.54/share 94,698 $12.75/share Stock-Based Compensation Expense Stock-based compensation expense related to our stock option plans was $26,652 $23,978 three March 31, 2019 2018, March 31, 2019, $183,731 2.0 Additionally, during the three March 31, 2019 2018 $126,572 $28,571, March 31, 2019, $72,509 second 2019.

Note 10 - Income Taxes

Note 10 - Income Taxes	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Income Tax Disclosure [Text Block]	10. Because of our historically significant net operating losses, we have not 382

Note 11 - Grants and Collaborat

Note 11 - Grants and Collaboration Revenue	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Government Grants and Contracts [Text Block]	11. We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During the three March 31, 2019 2018, $354,319 $216,299, March 31, 2019, $2,525,419 2019 2020. During the three March 31, 2019 2018, $9,913 $5,000, third

Note 12 - Subsequent Events

Note 12 - Subsequent Events	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	12. Preferred Stock Transactions On April 26, 2019, $250,000 250 9 33,334 May 2019, 94 53,600 Reverse Stock Split On April 30, 2019, one five hundred

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, 2019 December 31, 2018 Laboratory equipment $ 534,578 $ 530,306 Leasehold improvements 115,605 115,605 Other furniture, fixtures & equipment 28,685 28,685 Total property and equipment 678,868 674,596 Accumulated depreciation and amortization (665,143 ) (663,246 ) Property and equipment, net $ 13,725 $ 11,350

Note 6 - Accrued Expenses (Tabl

Note 6 - Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, 2019 December 31, 2018 Accrued management salaries $ 1,026,467 $ 924,509 Accrued directors’ fees 333,870 295,670 Other accrued expenses 18,373 18,373 Total accrued expenses $ 1,378,710 $ 1,238,552

Note 2 - Basis of Presentation

Note 2 - Basis of Presentation (Details Textual)	Apr. 30, 2019
Subsequent Event [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	500

Note 4 - Basic and Diluted Lo_2

Note 4 - Basic and Diluted Loss Per Common Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	589,000	446,000

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Property and equipment, gross	$ 678,868	$ 674,596
Accumulated depreciation and amortization	(665,143)	(663,246)
Property and equipment, net	13,725	11,350
Laboratory Equipment [Member]
Property and equipment, gross	534,578	530,306
Leasehold Improvements [Member]
Property and equipment, gross	115,605	115,605
Other Furniture Fixtures And Equipment [Member]
Property and equipment, gross	$ 28,685	$ 28,685

Note 6 - Accrued Expenses - Sch

Note 6 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Accrued management salaries	$ 1,026,467	$ 924,509
Accrued directors’ fees	333,870	295,670
Other accrued expenses	18,373	18,373
Total accrued expenses	$ 1,378,710	$ 1,238,552

Note 7 - Notes Payable (Details

Note 7 - Notes Payable (Details Textual) - USD ($)	Feb. 28, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 27, 2018
Proceeds from Notes Payable, Total			$ 50,000
Interest Expense, Total		1,128	208
Term Notes [Member]
Debt Instrument, Face Amount				$ 250,000
Common Stock Purchase Warrants [Member]
Warrants and Rights Outstanding, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	358
Warrants issued to two current investors [Member]
Warrants and Rights Outstanding, Term				3 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				20,000
Senior Notes [Member]
Proceeds from Notes Payable, Total	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	5.00%
Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year		8,333
Long-term Debt, Maturities, Repayments of Principal in Year Two		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Three		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Four		12,500
Long-term Debt, Maturities, Repayments of Principal in Year Five		2,083
Interest Expense, Total		$ 621	$ 208

Note 8 - Commitments (Details T

Note 8 - Commitments (Details Textual)	3 Months Ended
	Mar. 31, 2019USD ($)ft²	Mar. 31, 2018USD ($)
Area of Real Estate Property | ft²	8,400
Operating Leases, Rent Expense, Total	$ 40,316	$ 39,136
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 120,949
Lessee, Operating Lease, Renewal Term	1 year
Unrecorded Unconditional Purchase Obligation, Total	$ 487,000

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Details Textual) - USD ($)	Feb. 28, 2019	Feb. 26, 2019	Feb. 18, 2019	Mar. 31, 2019	Feb. 28, 2019	Mar. 31, 2019	Mar. 31, 2018	Feb. 25, 2019	Dec. 31, 2018	Feb. 28, 2018
Preferred Stock, Par or Stated Value Per Share				$ 0.01		$ 0.01			$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance				29,441		29,441
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance				$ 53.19		$ 53.19
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number				13,585		13,585
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price				$ 93.92		$ 93.92
Share-based Payment Arrangement, Expense						$ 26,652	$ 23,978
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total				$ 183,731		$ 183,731
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition						2 years
Stock Issued During Period, Value Expensed During the Period, Issued for Services						$ 126,572	$ 28,571
Prepaid Expense, Value of Stock Issued for Services During Period				$ 72,509		$ 72,509
Series I Warrants [Member]
Convertible Preferred Stock and Related Warrants Issued		33,334
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 7.50
Class of Warrant or Right, Number of Securities Called by Warrants or Rights		66,668
Common Stock Purchase Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights										358
Class Of Warrant Or Right Issued During Period						33,334
Class of Warrant or Right, Outstanding				148,032		148,032
Class Of Warrant Or Right Outstanding Weighted Average Exercise Price				$ 11.54		$ 11.54
Class Of Warrant Or Right Exercisable Number				94,698		94,698
Class Of Warrant Or Right Exercisable Weighted Average Exercise Price				$ 12.75		$ 12.75
Series G Convertible Preferred Stock and Related Warrants [Member]
Convertible Preferred Stock and Related Warrants, Authorized	1,000
Proceeds from Issuance of Convertible Preferred Stock and Related Warrants, Maximum	$ 1,000,000	$ 250,000
Convertible Preferred Stock and Related Warrants Issued		500
Conversion of Series C Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted					587	587
Conversion of Stock, Shares Issued					78,280	78,280
Conversion of Series F Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted				180		180
Conversion of Stock, Shares Issued				40,000		40,000
Conversion from Series C and F Convertible Preferred Stock to Common Stock [Member]
Conversion of Stock, Shares Issued						118,280
Series B Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance				100		100			100
Convertible Preferred Stock, Conversion Price1				$ 175		$ 175
Conversion of Stock, Shares Converted						0
Preferred Stock, Par or Stated Value Per Share				$ 1,000		$ 1,000			$ 1,000
Series F Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance				2,583		2,583
Convertible Preferred Stock, Conversion Price1			$ 7.50
Number of Series C and Series E Preferred Stock Exchanged for Series F Convertible Preferred Stock			2,763
Preferred Stock, Par or Stated Value Per Share			$ 1,000
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock			90.00%
Series E Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance				0		0			1,200
Preferred Stock, Par or Stated Value Per Share				$ 1,000		$ 1,000			$ 1,000
Series G Convertible Preferred Stock [Member]
Convertible Preferred Stock, Conversion Price1								$ 7.50
Conversion of Stock, Shares Converted						0
Preferred Stock, Par or Stated Value Per Share								$ 1,000
Convertible Preferred Stock, Conversion Price, Percentage of Volume Weighted Average Price of the Common Stock								90.00%
Series C Convertible Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance				0		0			2,150
Preferred Stock, Par or Stated Value Per Share				$ 1,000		$ 1,000			$ 1,000

Note 11 - Grants and Collabor_2

Note 11 - Grants and Collaboration Revenue (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue from Contract with Customer, Including Assessed Tax	$ 364,232	$ 221,299
NIH Grants [Member]
Revenue from Contract with Customer, Including Assessed Tax	354,319	216,299
Unused Grant Funds	2,525,419
Research Agreements [Member]
Revenue from Contract with Customer, Including Assessed Tax	$ 9,913	$ 5,000

Note 12 - Subsequent Events (De

Note 12 - Subsequent Events (Details Textual)	May 12, 2019shares	Apr. 30, 2019	Apr. 26, 2019USD ($)shares	Mar. 31, 2019shares	Mar. 31, 2019USD ($)shares	Mar. 31, 2018USD ($)
Proceeds from Issuance of Convertible Preferred Stock | $					$ 240,000	$ 590,000
Conversion of Series F Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted				180	180
Conversion of Stock, Shares Issued				40,000	40,000
Series G Convertible Preferred Stock [Member]
Conversion of Stock, Shares Converted					0
Subsequent Event [Member] | Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		500
Subsequent Event [Member] | Conversion of Series F Preferred Stock Into Common Stock [Member]
Conversion of Stock, Shares Converted	94
Conversion of Stock, Shares Issued	53,600
Subsequent Event [Member] | Series I Warrants [Member]
Class Of Warrant Or Right Issued During Period			33,334
Subsequent Event [Member] | Series G Convertible Preferred Stock [Member]
Proceeds from Issuance of Convertible Preferred Stock | $			$ 250,000
Stock Issued During Period, Shares, New Issues			250